# Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk

> **NCT07374718** · NA · NOT_YET_RECRUITING · sponsor: **Shenyang Northern Hospital** · enrollment: 468 (estimated)

## Conditions studied

- Acute Coronary Syndrome (ACS)
- High Bleeding Risk(HBR)
- Coronary Artery Disease (CAD)

## Interventions

- **DEVICE:** IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy
- **DEVICE:** Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)

## Key facts

- **NCT ID:** NCT07374718
- **Lead sponsor:** Shenyang Northern Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 468 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07374718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07374718, "Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07374718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*